Cell-Free DNA Screening for Aneuploidy and Microdeletion Syndromes

Brian Shaffer, Mary E. Norton

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Cell-free DNA (cfDNA) screening for the common aneuploidies is an accurate noninvasive screen for the common autosomal and sex chromosome aneuploidies. However, cfDNA screening should not be considered a diagnostic test, and the positive predictive value should be used in counseling women with a positive test regarding the option for diagnostic testing. Compared with traditional screening, cfDNA may not detect as many chromosomal abnormalities of importance. Furthermore, due to the low prevalence of recurrent copy number variants, the clinical utility in screening for microdeletions and duplications is uncertain and is not recommended for the general obstetric population.

Original languageEnglish (US)
Pages (from-to)13-26
Number of pages14
JournalObstetrics and Gynecology Clinics of North America
Volume45
Issue number1
DOIs
StatePublished - Mar 1 2018

Fingerprint

Aneuploidy
DNA
Sex Chromosomes
Routine Diagnostic Tests
Chromosome Aberrations
Obstetrics
Counseling
Population

Keywords

  • Aneuploidy screening
  • Cell-free DNA screening
  • Noninvasive prenatal testing
  • Prenatal diagnosis
  • Prenatal screening

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Cell-Free DNA Screening for Aneuploidy and Microdeletion Syndromes. / Shaffer, Brian; Norton, Mary E.

In: Obstetrics and Gynecology Clinics of North America, Vol. 45, No. 1, 01.03.2018, p. 13-26.

Research output: Contribution to journalReview article

@article{404b745f5e514bdfaebf170e067e7a11,
title = "Cell-Free DNA Screening for Aneuploidy and Microdeletion Syndromes",
abstract = "Cell-free DNA (cfDNA) screening for the common aneuploidies is an accurate noninvasive screen for the common autosomal and sex chromosome aneuploidies. However, cfDNA screening should not be considered a diagnostic test, and the positive predictive value should be used in counseling women with a positive test regarding the option for diagnostic testing. Compared with traditional screening, cfDNA may not detect as many chromosomal abnormalities of importance. Furthermore, due to the low prevalence of recurrent copy number variants, the clinical utility in screening for microdeletions and duplications is uncertain and is not recommended for the general obstetric population.",
keywords = "Aneuploidy screening, Cell-free DNA screening, Noninvasive prenatal testing, Prenatal diagnosis, Prenatal screening",
author = "Brian Shaffer and Norton, {Mary E.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ogc.2017.10.001",
language = "English (US)",
volume = "45",
pages = "13--26",
journal = "Obstetrics and Gynecology Clinics of North America",
issn = "0889-8545",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Cell-Free DNA Screening for Aneuploidy and Microdeletion Syndromes

AU - Shaffer, Brian

AU - Norton, Mary E.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Cell-free DNA (cfDNA) screening for the common aneuploidies is an accurate noninvasive screen for the common autosomal and sex chromosome aneuploidies. However, cfDNA screening should not be considered a diagnostic test, and the positive predictive value should be used in counseling women with a positive test regarding the option for diagnostic testing. Compared with traditional screening, cfDNA may not detect as many chromosomal abnormalities of importance. Furthermore, due to the low prevalence of recurrent copy number variants, the clinical utility in screening for microdeletions and duplications is uncertain and is not recommended for the general obstetric population.

AB - Cell-free DNA (cfDNA) screening for the common aneuploidies is an accurate noninvasive screen for the common autosomal and sex chromosome aneuploidies. However, cfDNA screening should not be considered a diagnostic test, and the positive predictive value should be used in counseling women with a positive test regarding the option for diagnostic testing. Compared with traditional screening, cfDNA may not detect as many chromosomal abnormalities of importance. Furthermore, due to the low prevalence of recurrent copy number variants, the clinical utility in screening for microdeletions and duplications is uncertain and is not recommended for the general obstetric population.

KW - Aneuploidy screening

KW - Cell-free DNA screening

KW - Noninvasive prenatal testing

KW - Prenatal diagnosis

KW - Prenatal screening

UR - http://www.scopus.com/inward/record.url?scp=85041813765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041813765&partnerID=8YFLogxK

U2 - 10.1016/j.ogc.2017.10.001

DO - 10.1016/j.ogc.2017.10.001

M3 - Review article

C2 - 29428281

AN - SCOPUS:85041813765

VL - 45

SP - 13

EP - 26

JO - Obstetrics and Gynecology Clinics of North America

JF - Obstetrics and Gynecology Clinics of North America

SN - 0889-8545

IS - 1

ER -